A pilot study assessing acceptability and feasibility of hatha yoga for chronic pain in people receiving opioid agonist therapy for opioid use disorder.
Buprenorphine
Chronic pain
Methadone
Yoga
Journal
Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
10
04
2019
revised:
23
07
2019
accepted:
23
07
2019
entrez:
25
8
2019
pubmed:
25
8
2019
medline:
18
8
2020
Statut:
ppublish
Résumé
The purpose of this project was to assess the feasibility and acceptability of a hatha yoga program designed to target chronic pain in people receiving opioid agonist therapy for opioid use disorder. We conducted a pilot randomized trial in which people with chronic pain who were receiving either methadone maintenance therapy (n = 20) or buprenorphine (n = 20) were randomly assigned to weekly hatha yoga or health education (HE) classes for 3 months. We demonstrated feasibility in many domains, including recruitment of participants (58% female, mean age 43), retention for follow-up assessments, and ability of teachers to provide interventions with high fidelity to the manuals. Fifty percent of participants in yoga (95% CI: 0.28-0.72) and 65% of participants in HE (95% CI: 0.44-0.87) attended at least 6 of 12 possible classes (p = 0.62). Sixty-one percent in the yoga group reported practicing yoga at home, with a mean number of times practicing per week of 2.67 (SD = 2.37). Participant mood improved pre-class to post-class, with greater decreases in anxiety and pain for those in the yoga group (p < 0.05). In conclusion, yoga can be delivered on-site at opioid agonist treatment programs with home practice taken up by the majority of participants. Future research may explore ways of increasing the yoga "dosage" received. This may involve testing strategies for increasing either class attendance or the amount of home practice or both.
Identifiants
pubmed: 31443887
pii: S0740-5472(19)30219-3
doi: 10.1016/j.jsat.2019.07.015
pmc: PMC6709876
mid: NIHMS1536254
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Methadone
UC6VBE7V1Z
Banques de données
ClinicalTrials.gov
['NCT03022890']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-27Subventions
Organisme : NCCIH NIH HHS
ID : R34 AT009432
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Drug Alcohol Depend. 2004 Feb 7;73(2):199-207
pubmed: 14725960
Cochrane Database Syst Rev. 2017 Jan 12;1:CD010671
pubmed: 28076926
J Pain. 2003 Sep;4(7):407-14
pubmed: 14622683
Psychopharmacol Bull. 1986;22(2):343-81
pubmed: 3774930
Psychol Med. 2017 Sep;47(12):2130-2142
pubmed: 28382883
Complement Ther Clin Pract. 2017 Nov;29:130-135
pubmed: 29122250
J Subst Abuse Treat. 2017 Apr;75:62-96
pubmed: 28153483
J Neurosci Rural Pract. 2018 Jan-Mar;9(1):117-122
pubmed: 29456355
Nicotine Tob Res. 2019 Oct 26;21(11):1517-1523
pubmed: 30295912
J Pain Res. 2011;4:189-201
pubmed: 21887116
Pain Med. 2019 Jan 1;20(1):119-128
pubmed: 29514333
Br J Anaesth. 2008 Jul;101(1):17-24
pubmed: 18487245
Altern Ther Health Med. 1997 Jul;3(4):57-66
pubmed: 9210777
Pain. 2000 Apr;85(3):317-332
pubmed: 10781906
J Altern Complement Med. 2015 Mar;21(3):152-8
pubmed: 25695849
J Gen Intern Med. 2009 Apr;24(4):482-8
pubmed: 19189194
J Subst Abuse Treat. 2019 Jan;96:58-64
pubmed: 30466550
Cochrane Database Syst Rev. 2012 Nov 14;11:CD007407
pubmed: 23152245
JAMA. 2003 May 14;289(18):2370-8
pubmed: 12746360
Complement Ther Med. 2013 Jun;21(3):244-52
pubmed: 23642957
Int J Yoga. 2015 Jul-Dec;8(2):144-7
pubmed: 26170596
J Psychiatr Res. 2017 Nov;94:194-201
pubmed: 28750232
J Subst Abuse Treat. 2016 Dec;71:54-57
pubmed: 27776678
Med Care. 2014 Apr;52(4):322-7
pubmed: 24556895
J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86
pubmed: 11132119
Ann Intern Med. 2017 Apr 04;166(7):493-505
pubmed: 28192793
Drug Alcohol Depend. 2005 Apr 4;78(1):65-71
pubmed: 15769559
Evid Based Complement Alternat Med. 2016;2016:5859729
pubmed: 27413387
Nurs Res. 2013 Jul-Aug;62(4):260-8
pubmed: 23715475
Am J Addict. 2013 Jan;22(1):75-83
pubmed: 23398230
Trials. 2014 Feb 26;15:67
pubmed: 24568299
J Pain. 2012 Jan;13(1):1-9
pubmed: 22178433
Drug Alcohol Depend. 2015 Dec 1;157:143-9
pubmed: 26518253
J Altern Complement Med. 2017 Jul;23(7):541-544
pubmed: 28488881
J Subst Abuse Treat. 2014 Aug;47(2):140-5
pubmed: 24814051
Ann Acad Med Singap. 1994 Mar;23(2):129-38
pubmed: 8080219
J Opioid Manag. 2018 Sep/Oct;14(5):345-358
pubmed: 30387858
Behav Res Ther. 2018 Dec;111:52-56
pubmed: 30312895
N Engl J Med. 2016 Mar 31;374(13):1253-63
pubmed: 27028915
Med Clin North Am. 2018 Jul;102(4):xvii-xviii
pubmed: 29933831
Pain. 2016 Apr;157(4):931-937
pubmed: 26683238
Drug Alcohol Depend. 2007 Sep 6;90(1):64-71
pubmed: 17386981
Pain. 2012 Jun;153(6):1148-1158
pubmed: 22494920
J Gen Intern Med. 2015 Jul;30(7):935-41
pubmed: 25678375
J Subst Abuse Treat. 2010 Dec;39(4):378-83
pubmed: 20727704
Int J Yoga Therap. 2018 Nov;28(1):23-38
pubmed: 29498893
Asian J Psychiatr. 2017 Feb;25:191-196
pubmed: 28262148
J Clin Med. 2018 Aug 01;7(8):
pubmed: 30071662
J Pain. 2014 Oct;15(10):979-84
pubmed: 25267013
Ann Intern Med. 2005 May 3;142(9):776-85
pubmed: 15867410
Curr Opin HIV AIDS. 2014 Jul;9(4):317-24
pubmed: 24824888
J Consult Clin Psychol. 2014 Jun;82(3):448-459
pubmed: 24491075
J Pain. 2015 Sep;16(9):887-94
pubmed: 26101814
Eval Program Plann. 1983;6(3-4):299-313
pubmed: 10267258
J Nurs Scholarsh. 2016 Jul;48(4):345-53
pubmed: 27149578
J Subst Abuse Treat. 2015 Jan;48(1):43-8
pubmed: 25171955
Complement Ther Med. 2014 Jun;22(3):441-5
pubmed: 24906582